NF2105

NF2105 is an investigational small molecule tyrosine kinase inhibitor (TKI) developed by Shenzhen Taili Biomedical and Shenzhen Xinyang Weikang Technology for the treatment of chronic myeloid leukemia (CML). It is designed as a potent inhibitor of the BCR-ABL1 fusion protein, specifically targeting the T315I gatekeeper mutation which confers resistance to first-, second-, and some third-generation TKIs. By binding to the ATP-binding site of the ABL1 kinase domain, NF2105 suppresses the constitutive signaling activity that drives leukemic cell proliferation. The drug is currently undergoing early-phase clinical evaluation in China to determine its safety, tolerability, and preliminary efficacy in patients with Philadelphia chromosome-positive (Ph+) leukemias who have failed prior therapies.